Evidence

Clyde has worked closely with the majority of large pharmaceutical companies, CiPA, HESI and the FDA to validate the CellOPTIQ® platform.
A broad range of reference and therapeutic compounds have been tested to demonstrate that CellOPTIQ®:

  • Is predictive of the clinical setting (correlates well with patient ECG)
  • Is predictive of in vivo models especially compounds with multi ion channel effects or effects on contractility
  • Offers significant advantages over other platforms
  • Provides very low false negative liability

Validation Experiments with Pharmaceutical Companies’ Compounds Demonstrate the Power of CellOPTIQ®

Case 3 European Pharma
Case 4 European Pharma

Comparison of CellOPTIQ with Rabbit Wedge and Other Modalities Using 19 Reference Compounds

Comparison of CellOPTIQ with Rabbit Wedge and Other Modalities Using 19 Reference Compounds

CellOPTIQ® outclasses many of the comparable platforms, especially in the identification of known reference compounds. CellOPTIQ® was the only platform without a false negative liability.

CellOPTIQ® Generates Data Which is Predictive of the Clinical Setting

Positive correlation observed between results of Axiogenesis hiPSC-CMs tested in vitro on CellOPTIQ® system and human EP treated with same range of Quinidine concentrations.

Voltage Sensitive Dye Quinidine - Axiogenesis cells

“I would do a voltage sensitive dye study on the myocyte” – Major Pharma, Global Head of Safety
“A reasonable approach” – FDA Physician